BACKGROUND: Glioblastoma is a malignant and aggressive type of central nevous system malignancy characterized by many distinct biological features including extensive hypoxia. Hypoxia in glioblatoma associates with complex signaling patterns including activation of several pathways such as MAPK, PI3K-AKT/mTOR and IL-6/JAK/STAT3 with the master regulator HIF-1, which in turn drive particular tumor behaviors determining, in the end, treatment outcomes and patients fate. Thus, the present study was designed to investigate the expression of selected hypoxia related factors including STAT3 in a small set of long-term surviving glioma patients. METHODS: The expression of selected hypoxia related factors including STAT3 was evaluated in a time series of formalin fixed paraffin embedded and cryopreserved glioma samples from repeatedly resected patients. In addition, comparative studies were also conducted on primary glioma cells derived from original patient samples, stabilized glioma cell lines and tumor-xenograft mice model. Obtained data were correlated with clinical findings too. RESULTS: Glioblastoma samples of the analyzed patients displayed heterogeneity in the expression of hypoxia- related and EMT markers with most interesting trend being observed in pSTAT3. This heterogeneity was subsequently confirmed in other employed models (primocultures derived from glioblastoma tissue resections, cryopreserved tumor specimens, stabilized glioblastoma cell line in vitro and in vivo) and concerned, in particular, STAT3 expression which remained stable. In addition, subsequent studies on the role of STAT3 in the context of glioblastoma hypoxia demonstrated opposing effects of its deletion on cell viability as well as the expression of hypoxia and EMT markers. CONCLUSIONS: Our results suport the importance of STAT3 expression and activity in the context of hypoxia in malignant glioblastoma long-term surviving glioma patients while emphasizing heterogeneity of biological outcomes in varying employed tumor models.

Department of Chemistry Faculty of Sciences University of Hradec Kralove Hradec Kralove Czech Republic

Department of Medical Biology and Genetics Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Department of Neurosurgery Faculty of Medicine in Hradec Kralove University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine in Hradec Kralove Charles University University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University General University Hospital Prague Prague Czech Republic

Department of Pathology Military University Hospital Prague Prague Czech Republic

The Fingerland Department of Pathology Faculty of Medicine n Hradec Kralove Charles University University Hospital Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Mohammed S, Dinesan M, Ajayakumar T. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother. 2022;27(6):1026–36. doi: 10.5603/RPOR.a2022.0113. PubMed DOI PMC

Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, et al. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY brain Tumor Funders’ Collaborative Consortium (EORTC 1419) Eur J Cancer. 2023;189:112913. doi: 10.1016/j.ejca.2023.05.002. PubMed DOI

Kalkan R. Hypoxia is the Driving Force behind GBM and could be a New Tool in GBM Treatment. Crit Rev Eukaryot Gene Expr. 2015;25(4):363–9. doi: 10.1615/CritRevEukaryotGeneExpr.2015015601. PubMed DOI

Cumino AC, Elissondo MC, Denegri GM. Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus Granulosus protoscoleces. Parasitol Int. 2009;58(3):270–7. doi: 10.1016/j.parint.2009.03.005. PubMed DOI

Park JH, Lee HK. Current understanding of Hypoxia in Glioblastoma Multiforme and its response to Immunotherapy. Cancers (Basel) 2022, 14(5). PubMed PMC

Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) 2015;3:83–92. doi: 10.2147/HP.S93413. PubMed DOI PMC

Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D’Agostino RB, Jr, Tatter SB, Laxton AW, et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020;10(1):15195. doi: 10.1038/s41598-020-72290-2. PubMed DOI PMC

Downes NL, Laham-Karam N, Kaikkonen MU, Yla-Herttuala S. Differential but complementary HIF1alpha and HIF2alpha transcriptional regulation. Mol Ther. 2018;26(7):1735–45. doi: 10.1016/j.ymthe.2018.05.004. PubMed DOI PMC

Liu Q, Cao P. Clinical and prognostic significance of HIF-1alpha in glioma patients: a meta-analysis. Int J Clin Exp Med. 2015;8(12):22073–83. PubMed PMC

Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr. 2013;4(1):5. PubMed PMC

Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res. 2010;70(3):925–35. doi: 10.1158/0008-5472.CAN-09-2715. PubMed DOI PMC

Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, Johnson RS, Goldrath AW. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol. 2013;14(11):1173–82. doi: 10.1038/ni.2714. PubMed DOI PMC

Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70. doi: 10.1038/s41392-023-01332-8. PubMed DOI PMC

Beig N, Patel J, Prasanna P, Hill V, Gupta A, Correa R, Bera K, Singh S, Partovi S, Varadan V, et al. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Sci Rep. 2018;8(1):7. doi: 10.1038/s41598-017-18310-0. PubMed DOI PMC

Skarkova V, Krupova M, Vitovcova B, Skarka A, Kasparova P, Krupa P, Kralova V, Rudolf E. The evaluation of Glioblastoma Cell Dissociation and its influence on its Behavior. Int J Mol Sci 2019, 20(18). PubMed PMC

Skarkova V, Kralova V, Krbal L, Matouskova P, Soukup J, Rudolf E. Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells. Exp Cell Res. 2018;369(2):295–303. doi: 10.1016/j.yexcr.2018.05.032. PubMed DOI

Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179. doi: 10.1093/nar/gni178. PubMed DOI PMC

Soukup J, Gerykova L, Rachelkar A, Hornychova H, Bartos MC, Krupa P, Vitovcova B, Pleskacova Z, Kasparova P, Dvorakova K et al. Diagnostic utility of immunohistochemical detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas. Diagnostics (Basel) 2023, 13(15). PubMed PMC

Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, Van Noorden CJ. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487–94. doi: 10.1007/s00401-010-0645-6. PubMed DOI PMC

Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, Francoise L, Carpentier AF, George B, Mandonnet E, Froelich S. IDH-Mutation is a weak predictor of long-term survival in Glioblastoma patients. PLoS ONE. 2015;10(7):e0130596. doi: 10.1371/journal.pone.0130596. PubMed DOI PMC

Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, et al. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathol. 2015;130(3):419–34. doi: 10.1007/s00401-015-1427-y. PubMed DOI

Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol. 2014;16(9):1186–95. doi: 10.1093/neuonc/nou043. PubMed DOI PMC

Spoor JKH, den Braber M, Dirven CMF, Pennycuick A, Bartkova J, Bartek J, van Dis V, van den Bosch TPP, Leenstra S, Venkatesan S. Investigating chromosomal instability in long-term survivors with glioblastoma and grade 4 astrocytoma. Front Oncol. 2023;13:1218297. doi: 10.3389/fonc.2023.1218297. PubMed DOI PMC

Vitovcova B, Skarkova V, Havelek R, Soukup J, Pande A, Caltova K, Rudolf E. Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest. Sci Rep. 2023;13(1):5993. doi: 10.1038/s41598-023-33047-9. PubMed DOI PMC

Lin GS, Chen YP, Lin ZX, Wang XF, Zheng ZQ, Chen L. STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. Int J Clin Exp Pathol. 2014;7(6):3141–9. PubMed PMC

Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008;14(24):8228–35. doi: 10.1158/1078-0432.CCR-08-1329. PubMed DOI PMC

Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 2017;19(7):887–96. doi: 10.1093/neuonc/now258. PubMed DOI PMC

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24(36):5552–60. doi: 10.1038/sj.onc.1208719. PubMed DOI

Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007;26(17):2435–44. doi: 10.1038/sj.onc.1210031. PubMed DOI

Fu W, Hou X, Dong L, Hou W. Roles of STAT3 in the pathogenesis and treatment of glioblastoma. Front Cell Dev Biol. 2023;11:1098482. doi: 10.3389/fcell.2023.1098482. PubMed DOI PMC

Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the U87MG glioma cell line: good news and bad news. Sci Transl Med. 2016;8(354):354re353. doi: 10.1126/scitranslmed.aaf6853. PubMed DOI

Pokorna M, Hudec M, Jurickova I, Vacha M, Polivkova Z, Kutna V, Pala J, Ovsepian SV, Cerna M. O’Leary VB: All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma. Brain Sci 2021, 11(6). PubMed PMC

Ge X, Pan MH, Wang L, Li W, Jiang C, He J, Abouzid K, Liu LZ, Shi Z, Jiang BH. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis. Cell Death Dis. 2018;9(11):1128. doi: 10.1038/s41419-018-1176-7. PubMed DOI PMC

Huang W, Ding X, Ye H, Wang J, Shao J, Huang T. Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1alpha pathway. NeuroReport. 2018;29(18):1578–85. doi: 10.1097/WNR.0000000000001156. PubMed DOI

Bronisz A, Salinska E, Chiocca EA, Godlewski J. Hypoxic Roadmap of Glioblastoma-learning about directions and distances in the Brain Tumor Environment. Cancers (Basel) 2020, 12(5). PubMed PMC

Collet S, Guillamo JS, Berro DH, Chakhoyan A, Constans JM, Lechapt-Zalcman E, Derlon JM, Hatt M, Visvikis D, Guillouet S, et al. Simultaneous mapping of vasculature, Hypoxia, and Proliferation using dynamic susceptibility contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed Glioblastoma. J Nucl Med. 2021;62(10):1349–56. doi: 10.2967/jnumed.120.249524. PubMed DOI PMC

Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82. doi: 10.1016/j.ccr.2006.11.020. PubMed DOI